Affymax and Takeda aim to submit Hematide to the FDA in 2011

08/5/2010 | Bloomberg Businessweek

Affymax and Japanese partner Takeda Pharmaceutical plan to file for FDA approval of anemia treatment Hematide during the first half of next year. Affymax said it will pursue an application for the treatment of anemia in dialysis patients and continue evaluating the drug's nondialysis use.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX